Fortis Healthcare Limited announced its audited consolidated financial results for the quarter and year ended March 31, 2026. The company reported strong financial performance with significant growth in both revenue and profitability for the full year. The board of directors recommended a final dividend of ₹1 per equity share, subject to shareholder approval. The company also disclosed that the newspaper publication of these audited financial results under Regulation 47 of SEBI (LODR) Regulations, 2015, was scheduled for May 23, 2026, in the Financial Express and Rozana Spokesman.

Consolidated Financial Performance

For the financial year 2026, Fortis Healthcare delivered robust growth. Consolidated revenue from operations increased by 17.3% to ₹9,128 Cr, compared to ₹7,783 Cr in the previous year. Profit After Tax (PAT) rose by 31.5% to ₹1,064 Cr from ₹809 Cr in FY25. Operating EBITDA for the year stood at ₹2,085 Cr, up 31.3% year-on-year, with an improved margin of 22.8% compared to 20.4% in FY25.

The table below summarises the key consolidated financial metrics for FY26:

The financial results include exceptional items. For FY26, a net exceptional loss of ₹22.2 Cr was recognised, primarily pertaining to the one-time impact of new Labour Codes, set off by a reversal of impairment in an associate company.

Quarterly Performance (Q4 FY26)

In the fourth quarter of FY26, Fortis Healthcare reported consolidated revenue of ₹2,365 Cr, a 17.8% increase from ₹2,007 Cr in Q4 FY25. Operating EBITDA grew to ₹531 Cr, with margins at 22.51% compared to 21.93% in the corresponding quarter of the previous year. Profit After Tax for Q4 FY26 stood at ₹271 Cr, up 44.2% year-on-year.

The table below presents the key Q4 financial metrics:

Segment Performance

The hospital business continued to be the primary growth driver, with revenue increasing 19.1% to ₹7,773 Cr in FY26. The segment reported an operating EBITDA of ₹1,724 Cr and a margin of 22.2%. Key operational metrics included an average revenue per occupied bed (ARPOB) of ₹2.51 Cr per annum and an occupancy rate of 68%.

The diagnostics business reported revenue of ₹1,527 Cr, an 8.5% increase over the previous year. Operating EBITDA for the segment surged 44.7% to ₹360 Cr, with margins improving to 23.6% from 17.7% in FY25.

Dividend and Corporate Developments

The board recommended a final dividend of ₹1 per equity share, equivalent to 10% of the face value of ₹10 each, subject to approval by shareholders at the Annual General Meeting. During the year, the company expanded its network through acquisitions, adding approximately 500 beds via the acquisition of People Tree Hospital in Bengaluru and Shrimann Hospital in Jalandhar. The company also entered into a long-term lease arrangement for the Greater Noida Hospital. As of March 31, 2026, Fortis Healthcare's net debt stood at ₹2,334 Cr, with a net debt to EBITDA ratio of 1.09x.

Fortis Healthcare has announced a significant capacity expansion plan, targeting the addition of 2,000 beds over the next three years. As part of this phased rollout, 500 beds are expected to become operational in 2027, marking an important milestone in the company's growth strategy.

Capacity Expansion at a Glance

The planned bed addition reflects Fortis Healthcare's commitment to scaling its hospital network to address increasing healthcare demand. The following table summarizes the key details of the announced expansion:

Phased Rollout Strategy

The expansion is being executed in a phased manner, with 500 beds slated for availability in 2027 as the first major tranche of the broader 2,000-bed addition. This structured approach allows Fortis Healthcare to systematically scale its infrastructure while managing operational readiness across its facilities.